Research & Investment Strategy

Global Factor Views

Macroeconomic and equity market backdrop

  • Near-term vaccine euphoria: Vaccine announcements by a number of drug companies in November led to a classic relief rally, with a rotation away from stocks with high earnings quality (which had led the market rally since its March low) and into lower quality and deep value stocks. The best performing areas of the market were those that have been most impacted by lockdowns (travel, hospitality and retail) as investors swiftly priced in a better outlook for earnings. The rotation from ‘high quality-low risk’ to ‘low quality-high risk’ witnessed in November was the largest since the recovery from the financial crisis low in March 2009.
  • Economic headwinds persist: The road to global recovery from the pandemic will take time. Infection rates remain high in the US and Europe, and ongoing restrictions and lockdowns continue to supress economic activity. Given the time required for an immunisation programme, we do not expect the good news on a vaccine to alter the trajectory of GDP growth in most developed nations before mid-2021.
  • Stimulus and market leadership: We expect central banks to maintain easy monetary policy for the foreseeable future. However, as we move through 2021 and into 2022, the role of fiscal stimulus should shift from recession mitigation to growth generation across a broad range of economic segments. Such an environment  should improve equity market breadth, supporting a wider group of stocks and investment styles than in 2020, where returns have been dominated by a narrow band of mega cap growth stocks.

With the above macro and market conditions as context, we update our outlook for equity market factors below.

Outlook for equity factors

Source: Rosenberg Equities, 9 December 2020. The views expressed above are as of the date of this document. No guarantee or warranty is made regarding the outlook above. Investors should not base their investment decisions on the commentary provided and should consult their advisers before doing so.

Source: Rosenberg Equities. Factor returns data presented as of Decmber 7th 2020. The chart plots univariate factor returns calcucated by Rosenberg Equities based on MSCI World investment universe. The data are shown for illustrative purposes only and are not based on actual portfolio returns. Past performance is not a guide to future performance.

This communication is for professional or institutional investors only and must not be relied upon by retail clients or investors. Circulation must be restricted accordingly. Any reproduction of this information, in whole or in part, is prohibited.

This material is published for informational purposes only and is neither an offer to enter into, or a term or condition of any business or agreement with the recipient or any other party, nor is it a solicitation for any services, securities, or funds herein, nor is it intended to provide investment, tax, or legal advice. If this material refers to funds, investments made therein are subject to the relevant fund documents. This material is not intended for distribution to persons or in jurisdictions where prohibited. No representation is made that any of the services, securities, or funds herein are suitable for any particular investor, and therefore, any prospective investor should consult their financial or other advisors about the appropriateness thereof. No representation or warranty is given as to the accuracy or completeness of this material. Investments may decrease in value and that past or backtested performance is no guide to future performance. Forward-looking or simulated data or information herein are subject to inherent limitations and are based upon assumptions that may not materialize, and may vary significantly from actual results. Investment models, research, and risk controls described herein do not guarantee against loss of principal or that any investment objectives shown herein will be achieved. The data, projections, forecasts, anticipations, hypotheses and/or opinions herein are subjective, and are not necessarily used or followed by the firm or its affiliates who may act based on their own opinions and as independent departments or entities within the organization. This information is always subject to change and all rights are reserved thereof. Performance shown, unless otherwise stated, is gross of management fees. An investor’s actual return will be reduced by management fees and other expenses the investor may incur.

If MSCI information appears herein, it may only be used for your internal use, it may not be reproduced or re-disseminated in any form, and it may not be used as a basis for, or a component of, any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. (www.mscibarra.com).

©2020 AXA Investment Managers. All rights reserved.

Please note that references to “Rosenberg Equities” herein refer solely to an expertise of AXA Investment Managers and not a specific legal entity. These materials are issued by the relevant AXA Investment Managers legal entity located in the recipient’s respective jurisdiction or region. Depending on the relevant issuing entity, the following additional disclosures may apply:

For Australian investors: AXA Investment Managers Asia (Singapore) Ltd (ARBN 115203622) is exempt from the requirement to hold an Australian Financial Services License and is regulated by the Monetary Authority of Singapore under Singaporean laws, which differ from Australian laws. AXA IM offers financial services in Australia only to residents who are “wholesale clients" within the meaning of Corporations Act 2001 (Cth).

For European investors: AXA Investment Managers UK Ltd is authorised and regulated by the Financial Conduct Authority in the United Kingdom. Registered in England and Wales No. 01431068. Registered Office: 7 Newgate Street, London EC1A 7NX. This material is intended for the use of persons meeting the MiFID client classification of Professional Clients or Eligible Counterparties and is not approved for communication to retail customers in any territory. The financial instruments used carry inherent risks which are unavoidable such as Market Risk, Credit Risk, Liquidity Risk and other risks. These risks are described in detail in our Risk Warnings document which is available upon request.

For Hong Kong investors: In Hong Kong, this document is issued by AXA Investment Managers Asia Limited (SFC License No. AAP809), which is authorized and regulated by Securities and Futures Commission. This document is to be used only by persons defined as “professional investor” under Part 1 of Schedule 1 to the Securities and Futures Ordinance (SFO) and other regulations, rules, guidelines or circulars which reference “professional investor” as defined under Part 1 of Schedule 1 to the SFO. This document must not be relied upon by retail investors. Circulation must be restricted accordingly. The authorisation of any fund by the Securities and Futures Commission in Hong Kong (“SFC”) does not imply official approval or recommendation. SFC authorization of a fund is not a recommendation or endorsement of a fund nor does it guarantee the commercial merits of a fund or its performance. It does not mean the fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. Where any of the Funds is not authorized by the SFC, the information contained herein in connection with such unauthorized Fund is solely for the use of professional investors in Hong Kong. Materials exempted from authorization by the SFC have not been reviewed by the SFC.

For Japanese investors: AXA Investment Managers Japan Ltd., whose registered office and principal place of business is at NBF Platinum Tower 14F 1-17-3 Shirokane, Minato-ku, Tokyo 108-0072, Japan, which is registered with the Financial Services Agency of Japan under the number KANTOZAIMUKYOKUCHO (KINSHO) 16, and is a member of Japan Securities Dealers Association, Type II Financial Instrument Firms Association, Investment Trust Association of Japan and Japan Investment Advisors Association to carry out the regulated activity of Financial Instrument Business under the Financial Instrument Exchange Law of Japan. In Japan, none of the funds mentioned in this document are registered under the Financial Instrument Exchange Law of Japan or Act on Investment Trusts and Investment Corporations. This document is purely for the information purpose for use by Qualified Institutional Investors defined by the Financial Instrument Exchange Law of Japan.

For Korean investors: In Korea, AXA Investment Managers Asia (Singapore) Ltd is a registered Cross Border Investment Advisor/Discretionary Investment Management Company under the Financial Investment Services and Capital Markets Act (the “Act”). The activities referenced under the Act are 5-2-2 Investment Advisory Business and 6-2-2 Discretionary Investment Management Business, respectively. Its financial services are available in Korea only to Professional Investors within the meaning of Article 10 of Enforcement Decree of the Financial Investment Services and Capital Markets Act. The relevant offering documents contain important information on selling restrictions and risk factors. You should read them carefully before entering into any transaction. It is your responsibility to be aware of and to observe all applicable laws and regulations of any relevant jurisdiction. To the extent that any fund is mentioned in this document, neither the fund nor AXA IM Asia is making any representation with respect to the eligibility of any recipients of this document to acquire the units/shares in the fund under the laws of Korea, including but without limitation the Foreign Exchange Transaction Act and Regulations thereunder. The units/shares have not been registered under the Financial Investment Services and Capital Markets Act of Korea, and none of the units/shares may be offered, sold or delivered, or offered or sold to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to applicable laws and regulations of Korea.

For Singapore investors: In Singapore, this document is issued by AXA Investment Managers Asia (Singapore) Ltd. (Registration No. 199001714W). This document is for use only by Institutional Investors as defined in Section 4A of the Securities and Futures Act (Cap. 289) and must not be relied upon by retail clients or investors. Circulation must be restricted accordingly.

For Swiss Investors: For Switzerland this information is intended exclusively for Qualified Investors according to Swiss law. Circulation must be restricted accordingly. The Swiss representative for the Irish-domiciled open-ended Unit Trust AXA Rosenberg Equity Alpha Trust, is First Independent Fund Services Ltd, Klausstrasse 33, CH-8008 Zurich. The Swiss paying agent is Credit Suisse, Paradeplatz 8, CH-8001 Zurich. The current prospectus, the Key Investor Information Document (the ‘KIID’) as well as the annual and semi-annual reports can be obtained free of charge from the Swiss representative. In respect of the units distributed in and from Switzerland, the place of jurisdiction is Zurich, Switzerland.

For US investors: Further information on AXA Rosenberg Investment Management LLC’s fees may be found in its Form ADV Part 2 or provided upon request. The collection of management fees produces a compounding effect on the total rate of return net of management fees. As an example, the effect of management fees on the total value of an investor’s portfolio assuming a) quarterly fee assessment, b) $1,000,000 investment, c) portfolio return of 8% a year, and d) 1.00% annual investment management fee would be $10,416 in the first year, and cumulatively $59,816 over five years and $143,430 over ten years.